Robert W. Baird reiterated coverage on Castle Biosciences with a new price target

3/9/21 8:13:31 AM ET

Medical Specialities

Health Care

Robert W. Baird reiterated coverage of Castle Biosciences with a rating of Outperform and set a new price target of $82.00 from $87.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CSTL

Date	Price Target	Rating	Analyst
12/14/2023	$25.00	Buy	Guggenheim
1/5/2023	$54.00	Sector Outperform	Scotiabank
1/7/2022	$59.00	Overweight	Stephens & Co.
11/9/2021	$85.00 → $75.00	Outperform	SVB Leerink
7/14/2021	$80.00 → $85.00	Outperform	SVB Leerink